Christopher Posner - Cara Therapeutics Director
| 69C Stock | EUR 4.84 0.00 0.00% |
Director
Mr. Christopher Posner is Director of the company. Mr. Posner has broad experience in commercial and marketing operations and product management at both large and specialty pharmaceutical companies, where he has focused on products for autoimmune, inflammatory and pain conditions, including Xeljanz and Enbrel. Since July 2017, he was the Chief Executive Officer of LEO Pharma, Inc. US, a subsidiary of LEO Pharma AS, a global healthcare company specializing in dermatology and critical care, including such conditions as psoriasis and atopic dermatitis. Prior to joining LEO, he was the Head of Worldwide Commercial Operations at RPharmaUS, LLC, a specialty pharmaceutical company focused on oncology and chronic immune disorders, from 2014 until 2017. Previously, Mr. Posner held a variety of senior management positions in commercial and marketing operations at BristolMyers Squibb Company, Pfizer Inc., Wyeth Pharmaceuticals, Inc. and Endo Pharmaceuticals plc. Mr. Posner holds an M.B.A. from Fuqua School of Business, Duke University and a B.A. in Economics from Villanova University. Mr. Posners extensive experience in the pharmaceutical industry, including in commercial and marketing operations, provides him with the qualifications to serve on the Board. since 2018.
| Age | 53 |
| Tenure | 7 years |
| Professional Marks | MBA |
| Phone | 203 406 3700 |
| Web | https://www.caratherapeutics.com |
Christopher Posner Latest Insider Activity
Tracking and analyzing the buying and selling activities of Christopher Posner against Cara Therapeutics stock is an integral part of due diligence when investing in Cara Therapeutics. Christopher Posner insider activity provides valuable insight into whether Cara Therapeutics is net buyers or sellers over its current business cycle. Note, Cara Therapeutics insiders must abide by specific rules, including filing SEC forms every time they buy or sell Cara Therapeutics'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Christopher Posner over a month ago Disposition of 372 shares by Christopher Posner of Cara Therapeutic at 4.72 subject to Rule 16b-3 | ||
Christopher Posner over three months ago Disposition of 3668 shares by Christopher Posner of Cara Therapeutic at 0.29 subject to Rule 16b-3 | ||
Christopher Posner over six months ago Disposition of 4149 shares by Christopher Posner of Cara Therapeutic at 0.35 subject to Rule 16b-3 | ||
Christopher Posner over six months ago Disposition of 36 shares by Christopher Posner of Cara Therapeutic at 0.75 subject to Rule 16b-3 |
Cara Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.2558) % which means that it has lost $0.2558 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.4516) %, meaning that it generated substantial loss on money invested by shareholders. Cara Therapeutics' management efficiency ratios could be used to measure how well Cara Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Cara Therapeutics has accumulated 4.99 M in total debt with debt to equity ratio (D/E) of 4.3, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Cara Therapeutics has a current ratio of 3.33, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Cara Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Cara Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Cara Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Cara to invest in growth at high rates of return. When we think about Cara Therapeutics' use of debt, we should always consider it together with cash and equity.
Cara Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. Cara Therapeutics, Inc. was founded in 2004 and is headquartered in Stamford, Connecticut. Cara Therapeutics operates under Biotechnology classification in Germany and is traded on Frankfurt Stock Exchange. It employs 55 people. Cara Therapeutics (69C) is traded on Frankfurt Exchange in Germany and employs 84 people. Management Performance
| Return On Equity | -0.45 | |||
| Return On Asset | -0.26 |
Cara Therapeutics Leadership Team
Elected by the shareholders, the Cara Therapeutics' board of directors comprises two types of representatives: Cara Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Cara. The board's role is to monitor Cara Therapeutics' management team and ensure that shareholders' interests are well served. Cara Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Cara Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Joana Goncalves, Chief Medical Officer | ||
| Christopher Posner, Director | ||
| Beth Weinberg, VP QA | ||
| Eric Vandal, VP Commercial | ||
| Frdrique Menzaghi, Chief RD | ||
| Iris Francesconi, Chief Relations | ||
| Scott Terrillion, Chief Compliance Officer, General Counsel, Secretary | ||
| Dr DSc, CoFounder Advisor | ||
| Ryan Maynard, Chief Officer |
Cara Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Cara Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.45 | |||
| Return On Asset | -0.26 | |||
| Profit Margin | (2.25) % | |||
| Operating Margin | (2.28) % | |||
| Current Valuation | 450.58 M | |||
| Shares Outstanding | 53.73 M | |||
| Shares Owned By Insiders | 16.10 % | |||
| Shares Owned By Institutions | 65.69 % | |||
| Price To Book | 3.33 X | |||
| Price To Sales | 14.36 X |
Currently Active Assets on Macroaxis
Other Information on Investing in Cara Stock
Cara Therapeutics financial ratios help investors to determine whether Cara Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Cara with respect to the benefits of owning Cara Therapeutics security.